1. Home
  2. DNUT vs MYGN Comparison

DNUT vs MYGN Comparison

Compare DNUT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$4.24

Market Cap

781.1M

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$6.55

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
MYGN
Founded
1937
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.1M
625.5M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
DNUT
MYGN
Price
$4.24
$6.55
Analyst Decision
Buy
Buy
Analyst Count
6
12
Target Price
$6.22
$11.82
AVG Volume (30 Days)
3.0M
1.0M
Earning Date
11-06-2025
11-03-2025
Dividend Yield
1.67%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,534,272,000.00
$825,300,000.00
Revenue This Year
N/A
$0.10
Revenue Next Year
$0.77
$5.28
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.21
52 Week Low
$2.50
$3.76
52 Week High
$10.06
$15.47

Technical Indicators

Market Signals
Indicator
DNUT
MYGN
Relative Strength Index (RSI) 49.78 40.20
Support Level $4.35 $6.51
Resistance Level $4.72 $6.89
Average True Range (ATR) 0.19 0.29
MACD -0.04 -0.06
Stochastic Oscillator 13.56 16.19

Price Performance

Historical Comparison
DNUT
MYGN

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: